Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome
Overview
Authors
Affiliations
Background: Telomere shortening is thought to be involved in the pathophysiology of myeloid malignancies, but telomere lengths (TL) during interphase and metaphase in hematopoietic malignancies have not been analyzed. We aimed to assess the TLs of interphase and metaphase cells of MDS and telomerase activity (TA) and to find out prognostic significances of TL and TA.
Methods: The prognostic significance of TA by quantitative PCR and TL by quantitative fluorescence in situ hybridization (QFISH) of interphase nuclei and metaphase chromosome arms of bone marrow cells from patients with MDS were evaluated.
Results: MDS patients had shorter interphase TL than normal healthy donors (P<0.001). Average interphase and metaphase TL were inversely correlated (P=0.013, p arm; P=0.029, q arm), but there was no statistically significant correlation between TA and TL (P=0.258). The progression free survival was significantly shorter in patients with high TA, but the overall survival was not different according to average TA or interphase TL groups. Multivariable Cox analysis showed that old age, higher International Prognostic Scoring System (IPSS) subtypes, transformation to AML, no history of hematopoietic stem cell transplantation and short average interphase TL (<433 TL) as independent prognostic factors for poorer survival (P=0.003, 0.001, 0.005, 0.005, and 0.013, respectively).
Conclusions: The lack of correlation between age and TL, TA, and TL, and the inverse relationship between TL and TA in MDS patients reflect the dysregulation of telomere status and proliferation. As a prognostic marker for leukemia progression, TA may be considered, and since interphase TL has the advantage of automated measurement by QFISH, it may be used as a prognostic marker for survival in MDS.
Harutyunyan T, Sargsyan A, Kalashyan L, Igityan H, Grigoryan B, Davtyan H Int J Mol Sci. 2024; 25(12).
PMID: 38928414 PMC: 11203595. DOI: 10.3390/ijms25126709.
Genomic landscape of TP53-mutated myeloid malignancies.
Abel H, Oetjen K, Miller C, Ramakrishnan S, Day R, Helton N Blood Adv. 2023; 7(16):4586-4598.
PMID: 37339484 PMC: 10425686. DOI: 10.1182/bloodadvances.2023010156.
Ali A, BenMohamed F, Decina A, Mukherjee S, Levi S, Garrido Castillo L Med Oncol. 2023; 40(7):204.
PMID: 37316755 PMC: 10267270. DOI: 10.1007/s12032-023-02064-z.
Telomere biology: from disorders to hematological diseases.
Roka K, Solomou E, Kattamis A Front Oncol. 2023; 13:1167848.
PMID: 37274248 PMC: 10235513. DOI: 10.3389/fonc.2023.1167848.
Genomic landscape of -mutated myeloid malignancies.
Abel H, Oetjen K, Miller C, Ramakrishnan S, Day R, Helton N medRxiv. 2023; .
PMID: 36711871 PMC: 9882519. DOI: 10.1101/2023.01.10.23284322.